tert-butyl (2-(didodecylamino)ethyl)carbamate | 1621174-93-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2-(didodecylamino)ethyl)carbamate
• 英文别名: tert-butyl N-[2-(didodecylamino)ethyl]carbamate
• CAS: 1621174-93-3
• 化学式: C₃₁H₆₄N₂O₂
• 分子量: 496.861
• InChiKey: BEROLJMJDRIYAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.1
• 重原子数：
  35
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(didodecylamino)ethyl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以49.8%的产率得到N¹,N¹-didodecylethan-1,2-diamine
  参考文献：
  名称：

  两类阿比特龙衍生物的合成

  摘要：

  本发明公开了两类阿比特龙衍生物的制备方法。第一类，以乙二胺为原料，采用(Boc)2O对氨基进行单保护，叔胺化，三氟乙酸脱保护得N1,N1‑二正烷基‑1,2‑二胺；阿比特龙与CDI反应，再与N1,N1‑二正烷基‑1,2‑二胺发生缩合反应，最后季铵盐化反应，制得不同烷烃链的β‑N‑甲基‑N1,N1‑二正烷基氨基甲酸‑Py‑N‑甲基‑阿比特龙酯。第二类同样以乙二胺为原料，采用(Boc)2O对氨基进行单保护，叔胺化，季铵盐化，三氟乙酸脱保护得N‑甲基‑N1,N1‑二烷基乙二胺；阿比特龙与对硝基氯甲酸苯酯反应，再与N‑甲基‑N1,N1‑二烷基乙二胺发生缩合反应，制得不同烷烃链的β‑N‑甲基‑N1,N1‑二正烷基氨基甲酸阿比特龙酯。上述阿比特龙衍生物含有亲水的季铵盐基团，相对阿比特龙，自制的两类阿比特龙衍生物可望具有较好的水溶性。

  公开号：

  CN106977577A
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 反应 60.0h， 生成 tert-butyl (2-(didodecylamino)ethyl)carbamate
  参考文献：
  名称：

  新型阳离子脂质的合成和表征：用于治疗肺癌和乳腺癌的 Survivin-siRNA Lipoplexes 的有效 siRNA 递送和抗癌活性**

  摘要：

  小干扰RNA (siRNA) 沉默疾病相关基因的能力使其成为近年来癌症基因治疗的可行途径。在这项研究中，我们设计并表征了具有阳离子脂质的脂质复合物，该脂质复合物可以有效地递送生存素 siRNA（肿瘤促进基因）并在体外和体内模型中协同其抗癌活性。

  DOI：

  10.1002/cmdc.202300097

文献信息

• [EN] LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF<br/>[FR] LIPIDOÏDES POUR LA TRANSFECTION D'ACIDES NUCLÉIQUES ET LEUR UTILISATION
  申请人：USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I

  公开号：WO2022063350A1

  公开（公告）日：2022-03-31

  The subject of the present invention is a lipidoid of general formula (I), wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The invention further describes transfection agents, transfection particles containing this lipidoid, and their use.

  本发明的主题是一种一般式（I）的脂质体，其中X、Y、Z和R如权利要求中所定义。该脂质体可用作转染剂。本发明还描述了转染剂、含有该脂质体的转染颗粒及其用途。
• 基于内源性二羧酸的可电离脂质及其制备方法与应用
  申请人：山东大学

  公开号：CN116082179A

  公开（公告）日：2023-05-09

  本发明属于生物医药技术领域，涉及基于内源性二羧酸的可电离脂质及其制备方法与应用。其为式(I)所示的化合物或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物； 其中，X选自‑CH基因治疗。
• Cationic lipid-conjugated hydrocortisone as selective antitumor agent
  作者：Bhowmira Rathore、Madhan Mohan Chandra Sekhar Jaggarapu、Anirban Ganguly、Hari Krishna Reddy Rachamalla、Rajkumar Banerjee

  DOI：10.1016/j.ejmech.2015.11.033

  日期：2016.1

  Hydrocortisone, the endogenously expressed steroidal, hormonal ligand for glucocorticoid receptor (GR), is body's natural anti-inflammatory and xenobiotic metabolizing agent. It has both palliative as well as adverse effects in different cancer patients. Herein, we show that conjugation product of C16-carbon chain-associated cationic lipid and hydrocortisone (namely, HYC16) induces selective toxicity in cancer (e.g. melanoma, breast cancer and lung adenocarcinoma) cells with least toxicity in normal cells, through induction of apoptosis and cell cycle arrest at G2/M phase. Further, significant tumor growth inhibition was observed in syngeneic melanoma tumor model with considerable induction of apoptosis in tumor associated cells. In contrast to hydrocortisone, significantly higher anti-angiogenic behavior of HYC16 helped in effective tumor shrinkage. This is the first demonstration to convert natural hormone hydrocortisone into a selective bioactive entity possessing anti-tumor effect. (C) 2015 Elsevier Masson SAS. All rights reserved.
• Cationic lipid-conjugated dexamethasone as a selective antitumor agent
  作者：Samaresh Sau、Rajkumar Banerjee

  DOI：10.1016/j.ejmech.2014.06.051

  日期：2014.8

  Dexamethasone (Dex) is one of the highly potent synthetic glucocorticoids. It exhibits prominent anti-inflammatory but moderate anti-proliferative activities. It is widely used along side chemotherapy to alleviate toxic side effects. Additionally, Dex is also a potent inducer of gluconeogenesis. However, its overuse critically desensitizes cells against chemotherapy. Herein, we report on the development of a new class of cationic lipid-Dex conjugates in which the C-8 carbon chain analogue (DX8) exhibited glucocorticoid receptor (GR)-mediated, caspase-3-assisted, cancer cell-selective anti-proliferative activity. Melanoma tumors in DX8-treated mice exhibited significantly reduced tumor aggressiveness with respect to tumors in Dex-treated mice. Tumor lysates prepared from DX8-treated group showed elevated levels of p53. DX8-treated cancer cells showed clear degradation of kinase JAK3/STAT3 protein levels. Additionally, DX8-treatment decreased the level of VEGFR2 in tumor-endothelial cells implying DX8's anti-proliferative roles in both tumor cells and tumor neovascular cells. Collectively, our results demonstrate potent anti-angiogenic, and selective JAK3/STAT3 down-regulating anticancer characteristics of DX8, a new dexamethasone-based antitumor molecule.